Analysis of the Modulation of the Tumor Microenvironment by MK-3475 (Pembrolizumab) Using a Systems Biology Approach (PEMSYS)

Clinical trial NCT03534635 · UNKNOWN

Trial details

NCT number: NCT03534635
Sponsor: Centre Hospitalier Universitaire Vaudois
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Metastatic Melanoma Naive to Immune Therapy in Metastatic Setting

Start date: 2018-06-01
Primary completion: 2026-06-01
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.